LAPTOP (NEAT44) – The Late Presenter Treatment Optimisation Study  

​

An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV-Disease 

​

Status:  Ongoing, (closed to recruitment) 

 

SPONSOR: NEAT ID Foundation 

 

Sponsor code: NEAT44 

EudraCT: 2018-003481-13 

 

Phase:  III

 

Indication:  ART-naïve HIV-1 infected patients

​

Sites: 55

​

Territories : 7

​

Publications :

Screening Characteristics abstract submitted to HIV Glasgow 2024 and approved as a poster.

 

Abstract submitted as late breaker to CROI 2025 and accepted as a poster.

 

Final manuscript published in Lancet Infectious Diseases, December 2025. "Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial." Georg M N Behrens, Lambert Assoumou, Geoffroy Liegeon, Andrea Antinori, Rafael Micán, Francesco G Genderini, Frank A Post, Jürgen K Rockstroh, Lisa Hamzah, Pere Domingo, Adrian Curran, Monserrat Laguno, Carl Fletcher, Jack Moody, Anton Pozniak, on behalf of the NEAT-ID Foundation and LAPTOP Study Team

​

​

​